AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company manufactures and sells two approved products, Feraheme (ferumoxytol) Injection for intravenous (IV) and GastroMARK. On June 30, 2009, Feraheme was approved for marketing in the United States by the United States Food and Drug Administration (FDA), for use as an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).